Iovance Biotherapeutics (IOVA) Competitors $1.77 +0.07 (+4.12%) Closing price 04:00 PM EasternExtended Trading$1.76 -0.01 (-0.28%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IOVA vs. ARWR, TWST, APLS, VCEL, RXRX, NAMS, APGE, DNLI, KNSA, and CGONShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Apellis Pharmaceuticals (APLS), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. Its Competitors Arrowhead Pharmaceuticals Twist Bioscience Apellis Pharmaceuticals Vericel Recursion Pharmaceuticals NewAmsterdam Pharma Apogee Therapeutics Denali Therapeutics Kiniksa Pharmaceuticals International CG Oncology Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Do institutionals and insiders have more ownership in ARWR or IOVA? 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 10.3% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend ARWR or IOVA? Arrowhead Pharmaceuticals currently has a consensus price target of $43.71, indicating a potential upside of 149.23%. Iovance Biotherapeutics has a consensus price target of $12.22, indicating a potential upside of 590.52%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Iovance Biotherapeutics 0 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, ARWR or IOVA? Arrowhead Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Is ARWR or IOVA more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -176.49%. Arrowhead Pharmaceuticals' return on equity of -45.33% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -45.33% -12.49% Iovance Biotherapeutics -176.49%-49.71%-39.18% Does the media refer more to ARWR or IOVA? In the previous week, Iovance Biotherapeutics had 34 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 37 mentions for Iovance Biotherapeutics and 3 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.20 beat Iovance Biotherapeutics' score of 0.04 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iovance Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 33 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, ARWR or IOVA? Iovance Biotherapeutics has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$3.55M682.33-$599.49M-$1.40-12.53Iovance Biotherapeutics$164.07M3.60-$372.18M-$1.24-1.43 SummaryIovance Biotherapeutics beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$567.69M$2.88B$5.46B$8.92BDividend YieldN/A2.44%5.24%4.04%P/E Ratio-1.4320.8027.0120.12Price / Sales3.60193.35380.1493.35Price / CashN/A41.7026.2128.59Price / Book0.767.487.995.57Net Income-$372.18M-$55.04M$3.16B$248.40M7 Day Performance1.72%5.44%3.69%6.04%1 Month Performance-13.66%2.38%2.91%7.69%1 Year Performance-75.75%5.53%34.30%20.97% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.7459 of 5 stars$1.77+4.1%$12.22+590.5%-76.6%$567.69M$164.07M-1.43500Trending NewsARWRArrowhead Pharmaceuticals3.7258 of 5 stars$15.99-0.6%$43.71+173.4%-34.1%$2.21B$3.55M-11.42400News CoverageTWSTTwist Bioscience4.4106 of 5 stars$36.69+2.1%$50.40+37.4%-26.6%$2.20B$312.97M-11.29990News CoverageAPLSApellis Pharmaceuticals4.4117 of 5 stars$17.45+0.1%$40.05+129.5%-51.9%$2.19B$781.37M-9.75770VCELVericel2.9496 of 5 stars$43.37+3.9%$61.14+41.0%-15.6%$2.18B$237.22M1,446.15300RXRXRecursion Pharmaceuticals1.9175 of 5 stars$5.07+0.8%$7.00+38.1%-32.7%$2.06B$58.84M-2.86400Trending NewsAnalyst ForecastNAMSNewAmsterdam Pharma2.256 of 5 stars$18.24-1.8%$42.89+135.1%-2.7%$2.05B$45.56M-9.704Positive NewsAnalyst UpgradeAPGEApogee Therapeutics2.9243 of 5 stars$44.12+1.7%$94.60+114.4%+3.2%$2.03BN/A-12.2691Trending NewsAnalyst ForecastOptions VolumeGap UpDNLIDenali Therapeutics4.5899 of 5 stars$13.98-0.9%$33.71+141.2%-32.6%$2.03BN/A-5.24430News CoverageKNSAKiniksa Pharmaceuticals International3.2633 of 5 stars$27.56-1.7%$38.80+40.8%+44.4%$2.01B$423.24M-110.24220Analyst UpgradeCGONCG Oncology2.3389 of 5 stars$26.11+0.6%$58.67+124.7%-17.7%$1.99B$1.14M-17.2961 Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Competitors Twist Bioscience Competitors Apellis Pharmaceuticals Competitors Vericel Competitors Recursion Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Apogee Therapeutics Competitors Denali Therapeutics Competitors Kiniksa Pharmaceuticals International Competitors CG Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOVA) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IOVA Stock Alerts